A Phase III Randomized, Open-label, Multicenter Clinical Study of IMM01 (Timdarpacept) in Combiniation With Tiselizumab Versus Physician's Choice Chemotherapy in PD-(L)1-refractory Classical Hodgkin Lymphoma
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Timdarpacept (Primary) ; Tislelizumab (Primary) ; Bendamustine; Gemcitabine
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Sponsors ImmuneOnco Biopharma
Most Recent Events
- 20 Jun 2024 New trial record